Stem Cell Transplantation (Sct) to Treat Severe Refractory Multiple Sclerosis (Ms)
Division of Haematology, Department of Internal Medicine, University of Patras, Greece
*Corresponding author: Athanasia Mouzaki, Division of Haematology, Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Patras, Rion, Patras GR-26500, Greece, Tel: +30-2610-969123, Fax: +30-2610-969123, E-mail: email@example.com
Int J Transplant Res Med Volume 1, Issue 1 Editorial IJTRM-1-002e
Received: February 16, 2015: Accepted: February 20, 2015: Published: February 23, 2015
Citation: Mouzaki A (2015) Stem Cell Transplantation (Sct) to Treat Severe Refractory Multiple Sclerosis (Ms). Int J Transplant Res Med 1:002e
Copyright: © 2015 Mouzaki A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
MS usually affects young adults aged between 20 to 40 years, although it can begin earlier or later in life. Women are affected almost twice as often as men. Symptoms include sensory disturbances in the limbs, optic nerve dysfunction, pyramidal tract dysfunction, bladder or bowel dysfunction, sexual dysfunction, ataxia and diplopia. In severe, drug-resistant MS, SCT was introduced as a treatment option about 20 years ago. Application of autologous SCT is based on the assumption that MS is not inherited in a Mendelian fashion and the autoreactive immune system can be replaced by a healthy one. Allogeneic SCT ensures that all leukocytes are of donor origin, but is applied rarely. Both approaches are fraught with problems resulting, mainly, from the high-intensity pre-transplant conditioning regimens. In certain reported cases, the patientsí condition worsened significantly after SCT. Overall, SCT has been applied to relatively few patients worldwide with moderate success, and recent studies suggest that patients with early highly aggressive MS benefit most from this treatment. Recent experimental studies have shown that re-myelination of MS lesions or, in general, CNS lesions, can be achieved by myelinogenic or neural stem cells via transplantation or by promoting neural and glial differentiation of endogenous cells.